Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer

Thomas B L Lam; Steven MacLennan; Karin Plass; Peter-Paul M Willemse; Malcolm D Mason; Philip Cornford; James Donaldson; Niall F Davis; Paolo Dell'Oglio; Christian Fankhauser; Nikos Grivas; Alexandre Ingels; Michael Lardas; Matthew Liew; Karl H Pang; Catherine Paterson; Muhammad I Omar; Fabio Zattoni; Karel T Buddingh; Thomas Van den Broeck; Marcus G Cumberbatch; Nicola Fossati; Tobias Gross; Lisa Moris; Ivo G Schoots; Roderick C N van den Bergh; Erik Briers; Stefano Fanti; Maria De Santis; Silke Gillessen; Jeremy P Grummet; Ann M Henry; Henk G van der Poel; Theodorus H van der Kwast; Olivier Rouvière; Derya Tilki; Thomas Wiegel; James N'Dow; Hendrik Van Poppel; Nicolas Mottet

doi:10.1016/j.eururo.2018.11.009

Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer

Thomas B L Lam
, Steven MacLennan
, Karin Plass
, Peter-Paul M Willemse
, Malcolm D Mason
, Philip Cornford
, James Donaldson
, Niall F Davis
, Paolo Dell'Oglio
, Christian Fankhauser
, Nikos Grivas
, Alexandre Ingels
, Michael Lardas
, Matthew Liew
, Karl H Pang
, Catherine Paterson
, Muhammad I Omar
, Fabio Zattoni
, Karel T Buddingh
, Thomas Van den Broeck

Marcus G Cumberbatch, Nicola Fossati, Tobias Gross, Lisa Moris, Ivo G Schoots, Roderick C N van den Bergh, Erik Briers, Stefano Fanti, Maria De Santis, Silke Gillessen, Jeremy P Grummet, Ann M Henry, Henk G van der Poel, Theodorus H van der Kwast, Olivier Rouvière, Derya Tilki, Thomas Wiegel, James N'Dow, Hendrik Van Poppel, Nicolas Mottet

Department of Urological Oncology

Research output: Contribution to journal › Letter › Academic

2 Downloads (Pure)

Original language	English
Pages (from-to)	699-702
Number of pages	4
Journal	European Urology
Volume	75
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2018.11.009
Publication status	Published - Apr 2019

Keywords

Consensus
Consensus Development Conferences as Topic
Delphi Technique
Evidence-Based Medicine
Humans
Male
Medical Oncology/standards
Multicenter Studies as Topic/methods
Prostatic Neoplasms/pathology
Research Design
Systematic Reviews as Topic
Treatment Outcome
Urology/standards

Access to Document

10.1016/j.eururo.2018.11.009

1-s2.0-S0302283818308662-mainFinal published version, 185 KBLicence: Taverne

Cite this

Lam, T. B. L., MacLennan, S., Plass, K., Willemse, P.-P. M., Mason, M. D., Cornford, P., Donaldson, J., Davis, N. F., Dell'Oglio, P., Fankhauser, C., Grivas, N., Ingels, A., Lardas, M., Liew, M., Pang, K. H., Paterson, C., Omar, M. I., Zattoni, F., Buddingh, K. T., ... Mottet, N. (2019). Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. European Urology, 75(4), 699-702. https://doi.org/10.1016/j.eururo.2018.11.009

@article{c8ce160565b442c69f03cab5137a9ea4,

title = "Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer",

keywords = "Consensus, Consensus Development Conferences as Topic, Delphi Technique, Evidence-Based Medicine, Humans, Male, Medical Oncology/standards, Multicenter Studies as Topic/methods, Prostatic Neoplasms/pathology, Research Design, Systematic Reviews as Topic, Treatment Outcome, Urology/standards",

author = "Lam, \{Thomas B L\} and Steven MacLennan and Karin Plass and Willemse, \{Peter-Paul M\} and Mason, \{Malcolm D\} and Philip Cornford and James Donaldson and Davis, \{Niall F\} and Paolo Dell'Oglio and Christian Fankhauser and Nikos Grivas and Alexandre Ingels and Michael Lardas and Matthew Liew and Pang, \{Karl H\} and Catherine Paterson and Omar, \{Muhammad I\} and Fabio Zattoni and Buddingh, \{Karel T\} and \{Van den Broeck\}, Thomas and Cumberbatch, \{Marcus G\} and Nicola Fossati and Tobias Gross and Lisa Moris and Schoots, \{Ivo G\} and \{van den Bergh\}, \{Roderick C N\} and Erik Briers and Stefano Fanti and \{De Santis\}, Maria and Silke Gillessen and Grummet, \{Jeremy P\} and Henry, \{Ann M\} and \{van der Poel\}, \{Henk G\} and \{van der Kwast\}, \{Theodorus H\} and Olivier Rouvi{\`e}re and Derya Tilki and Thomas Wiegel and James N'Dow and \{Van Poppel\}, Hendrik and Nicolas Mottet",

note = "Funding Information: Conflicts of interest: Thomas B.L. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Malcolm D. Mason is a company consultant for Ellipses Pharma and Oncotherics. Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; receives company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participates in trials run by Ferring; and receives fellowships and travel grants from Astellas and Janssen. Erik Briers has received grant and research support from Ipsen, the European Association of Urology, and Bayer; is an ex officio board member for Europa UOMO; is an ethics committee and advisory group member for REQUITE; is a patient advisory board member for PAGMI; and is a member of SCA and EMA PCWP. Stefano Fanti is a company consultant for Bayer and ANMI; has received speaker honoraria from Bayer, Genzyme, ANMI, and GE Healthcare; and participates in trials run by Amgen, Bayer, BMS, Genzyme, Janssen, Merck, and Novartis. Maria De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc, ESSA, Ferring, GSK, Incyte, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Piere Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials run by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, and SOTIO; and as a member of the EORTC GU group participates in various trials. She has received research grants from Pierre Fabre Oncologie, and travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreaon, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Silke Gillessen is a company consultant for AAA International, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxIVAX SA, Orion, Roche, Sanofi Aventis Group, Nectar, and ProteoMediX; has received speaker honoraria from Janssen and Novartis; and participates in multiple trials run by different companies. Ann M. Henry is a company consultant for Nucletron-Elektra; participates in trials run by Cancer Research UK and the National Institute of Health Research (UK); ahs received travel grants from the Medical Research Council, the National Institute of Health Research (UK), and Cancer Research UK; and has received research grants from Cancer Research UK and the Sir John Fisher Foundation. Henk G. van der Poel is a company consultant for Intuitive Surgical; has participated in trials for Astellas and Steba Biotech; and has received grant and research support from Astellas. Thomas Wiegel is an advisory board member for IPSEN; receives company speaker honoraria from IPSEN and Hexal; is a member of the Janssen Steering Committee; and has participated in the ATLAS/AUO trial. Olivier Rouvi{\`e}re has received company speaker honoraria from EDAP-TMS; participates in trials run by ESAO-TMS and Vermon; and has received research and travel grants from Philips. Derya Tilki is a company consultant for Steba Biotech and MDx Health; has received speaker honoraria from Mundipharma, Astellas, and Ribosepharm; participates in trials run by MDx Health; has received travel and research grants from Janssen; and is a member of the PIONEER consortium. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen and Ferring; and has received fellowships and travel grants from Astellas, IPSEN, Sanofi, Janssen and Roche. The remaining authors have nothing to disclose. ",

year = "2019",

month = apr,

doi = "10.1016/j.eururo.2018.11.009",

language = "English",

volume = "75",

pages = "699--702",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "4",

}

Lam, TBL, MacLennan, S, Plass, K, Willemse, P-PM, Mason, MD, Cornford, P, Donaldson, J, Davis, NF, Dell'Oglio, P, Fankhauser, C, Grivas, N, Ingels, A, Lardas, M, Liew, M, Pang, KH, Paterson, C, Omar, MI, Zattoni, F, Buddingh, KT, Van den Broeck, T, Cumberbatch, MG, Fossati, N, Gross, T, Moris, L, Schoots, IG, van den Bergh, RCN, Briers, E, Fanti, S, De Santis, M, Gillessen, S, Grummet, JP, Henry, AM, van der Poel, HG, van der Kwast, TH, Rouvière, O, Tilki, D, Wiegel, T, N'Dow, J, Van Poppel, H & Mottet, N 2019, 'Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer', European Urology, vol. 75, no. 4, pp. 699-702. https://doi.org/10.1016/j.eururo.2018.11.009

TY - JOUR

T1 - Study Protocol for the DETECTIVE Study

T2 - An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer

AU - Lam, Thomas B L

AU - MacLennan, Steven

AU - Plass, Karin

AU - Willemse, Peter-Paul M

AU - Mason, Malcolm D

AU - Cornford, Philip

AU - Donaldson, James

AU - Davis, Niall F

AU - Dell'Oglio, Paolo

AU - Fankhauser, Christian

AU - Grivas, Nikos

AU - Ingels, Alexandre

AU - Lardas, Michael

AU - Liew, Matthew

AU - Pang, Karl H

AU - Paterson, Catherine

AU - Omar, Muhammad I

AU - Zattoni, Fabio

AU - Buddingh, Karel T

AU - Van den Broeck, Thomas

AU - Cumberbatch, Marcus G

AU - Fossati, Nicola

AU - Gross, Tobias

AU - Moris, Lisa

AU - Schoots, Ivo G

AU - van den Bergh, Roderick C N

AU - Briers, Erik

AU - Fanti, Stefano

AU - De Santis, Maria

AU - Gillessen, Silke

AU - Grummet, Jeremy P

AU - Henry, Ann M

AU - van der Poel, Henk G

AU - van der Kwast, Theodorus H

AU - Rouvière, Olivier

AU - Tilki, Derya

AU - Wiegel, Thomas

AU - N'Dow, James

AU - Van Poppel, Hendrik

AU - Mottet, Nicolas

N1 - Funding Information: Conflicts of interest: Thomas B.L. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Malcolm D. Mason is a company consultant for Ellipses Pharma and Oncotherics. Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; receives company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participates in trials run by Ferring; and receives fellowships and travel grants from Astellas and Janssen. Erik Briers has received grant and research support from Ipsen, the European Association of Urology, and Bayer; is an ex officio board member for Europa UOMO; is an ethics committee and advisory group member for REQUITE; is a patient advisory board member for PAGMI; and is a member of SCA and EMA PCWP. Stefano Fanti is a company consultant for Bayer and ANMI; has received speaker honoraria from Bayer, Genzyme, ANMI, and GE Healthcare; and participates in trials run by Amgen, Bayer, BMS, Genzyme, Janssen, Merck, and Novartis. Maria De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc, ESSA, Ferring, GSK, Incyte, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Piere Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials run by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, and SOTIO; and as a member of the EORTC GU group participates in various trials. She has received research grants from Pierre Fabre Oncologie, and travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreaon, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Silke Gillessen is a company consultant for AAA International, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxIVAX SA, Orion, Roche, Sanofi Aventis Group, Nectar, and ProteoMediX; has received speaker honoraria from Janssen and Novartis; and participates in multiple trials run by different companies. Ann M. Henry is a company consultant for Nucletron-Elektra; participates in trials run by Cancer Research UK and the National Institute of Health Research (UK); ahs received travel grants from the Medical Research Council, the National Institute of Health Research (UK), and Cancer Research UK; and has received research grants from Cancer Research UK and the Sir John Fisher Foundation. Henk G. van der Poel is a company consultant for Intuitive Surgical; has participated in trials for Astellas and Steba Biotech; and has received grant and research support from Astellas. Thomas Wiegel is an advisory board member for IPSEN; receives company speaker honoraria from IPSEN and Hexal; is a member of the Janssen Steering Committee; and has participated in the ATLAS/AUO trial. Olivier Rouvière has received company speaker honoraria from EDAP-TMS; participates in trials run by ESAO-TMS and Vermon; and has received research and travel grants from Philips. Derya Tilki is a company consultant for Steba Biotech and MDx Health; has received speaker honoraria from Mundipharma, Astellas, and Ribosepharm; participates in trials run by MDx Health; has received travel and research grants from Janssen; and is a member of the PIONEER consortium. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen and Ferring; and has received fellowships and travel grants from Astellas, IPSEN, Sanofi, Janssen and Roche. The remaining authors have nothing to disclose.

PY - 2019/4

Y1 - 2019/4

KW - Consensus

KW - Consensus Development Conferences as Topic

KW - Delphi Technique

KW - Evidence-Based Medicine

KW - Humans

KW - Male

KW - Medical Oncology/standards

KW - Multicenter Studies as Topic/methods

KW - Prostatic Neoplasms/pathology

KW - Research Design

KW - Systematic Reviews as Topic

KW - Treatment Outcome

KW - Urology/standards

UR - https://www.scopus.com/pages/publications/85062005138

U2 - 10.1016/j.eururo.2018.11.009

DO - 10.1016/j.eururo.2018.11.009

M3 - Letter

C2 - 30473433

SN - 0302-2838

VL - 75

SP - 699

EP - 702

JO - European Urology

JF - European Urology

IS - 4

ER -

Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer

Keywords

Access to Document

Other files and links

Cite this